Motilium

The tablet contains 10 mg domperidone.
Excipients/Inactive Ingredients: The inactive ingredients are hydrogenated cottonseed oil, hypromellose, lactose monohydrate, magnesium stearate, maize starch, microcrystalline cellulose, polyvidone, pregelatinized potato starch, sodium lauryl sulphate.

Gastrokinetic/Antiemetic.
Pharmacology: Pharmacodynamics: Domperidone is a dopamine antagonist with anti-emetic properties. Domperidone does not readily cross the blood‑brain barrier. In domperidone users, especially in adults, extrapyramidal side effects are very rare, but domperidone promotes the release of prolactin from the pituitary. Its anti-emetic effect may be due to a combination of peripheral (gastrokinetic) effects and antagonism of dopamine receptors in the chemoreceptor trigger zone, which lies outside the blood‑brain barrier in the area postrema. Animal studies, together with the low concentrations found in the brain, indicate a predominantly peripheral effect of domperidone on dopamine receptors.
Studies in man have shown oral domperidone to increase lower esophageal pressure, improve antroduodenal motility and accelerate gastric emptying. There is no effect on gastric secretion.
Effect on QT/QTc Interval and Cardiac Electrophysiology: In accordance with ICH‑E14 guidelines, a thorough QT study was performed in healthy subjects. This study included a placebo, active comparator and positive control and was conducted using recommended and supra‑therapeutic doses (10 and 20 mg administered 4 times a day). This study found a maximal difference of QTc between domperidone and placebo in LS‑means in the change from baseline of 3.4 msec for 20 mg domperidone administered 4 times a day on Day 4, and the 2‑sided 90% CI (1.0 5.9 msec) did not exceed 10 msec. The QT prolongation observed in this study when domperidone was administered according to the recommended dosing regimen is not clinically relevant.
This lack of clinical relevance is corroborated by pharmacokinetics and QTc interval data from two older studies which involved a 5‑day treatment of 20 mg and 40 mg domperidone administered 4 times a day. ECGs were recorded prior to the study, on Day 5 at 1 hour (approximately at t_max) after the morning dose, and 3 days later. In both studies, no difference between QTc after active treatment and placebo was observed. It was therefore concluded that domperidone administration of 80 and 160 mg daily doses had no clinically significant effect on QTc in healthy subjects.
Pharmacokinetics: Absorption: In fasting subjects, domperidone is rapidly absorbed after oral administration, with peak plasma concentrations occurring at approximately 60 minutes after dosing. The key pharmacokinetic parameters after a single or multiple doses (administered 4 times a day) of 10 mg domperidone base tablets to healthy subjects are presented in the table as follows. The C_max and AUC values of domperidone increased proportionally with dose in the 10 mg to 20 mg dose range. (See Table 1.)

Click on icon to see table/diagram/image

The low absolute bioavailability of oral domperidone (approximately 15%) is due to an extensive first‑pass metabolism in the gut wall and liver. Although domperidone's bioavailability is enhanced in normal subjects when taken after a meal, patients with gastro-intestinal complaints should take domperidone 15-30 minutes before a meal. Reduced gastric acidity impairs the absorption of domperidone base. Oral bioavailability of domperidone base is decreased by prior concomitant administration of cimetidine and sodium bicarbonate. The time of peak absorption is slightly delayed and the AUC somewhat increased when the oral drug is taken after a meal.
Distribution: Domperidone is 91‑93% bound to plasma proteins. Distribution studies with radiolabelled drug in animals have shown wide tissue distribution, but low brain concentration. Small amounts of drug cross the placenta in rats.
Metabolism: Domperidone undergoes rapid and extensive hepatic metabolism by hydroxylation and N‑dealkylation. In vitro metabolism experiments with diagnostic inhibitors revealed that CYP3A4 is a major form of cytochrome P-450 involved in the N‑dealkylation of domperidone, whereas CYP3A4, CYP1A2 and CYP2E1 are involved in domperidone aromatic hydroxylation.
Excretion: Urinary and fecal excretions amount to 31 and 66% of the oral dose, respectively. The proportion of the drug excreted unchanged is small (10% of fecal excretion and approximately 1% of urinary excretion).
The plasma half‑life after a single oral dose is 7‑9 hours in healthy subjects, but is prolonged in patients with severe renal insufficiency.
Special Populations: Hepatic impairment: In subjects with moderate hepatic impairment (Pugh score 7 to 9, Child‑Pugh rating B), the AUC and C_max of domperidone is 2.9‑ and 1.5‑fold higher, respectively, than in healthy subjects. The unbound fraction is increased by 25%, and the terminal elimination half‑life is prolonged from 15 to 23 hours. Subjects with mild hepatic impairment have a somewhat lower systemic exposure than healthy subjects based on C_max and AUC, with no change in protein binding or terminal half‑life. Subjects with severe hepatic impairment were not studied (see Contraindications).
Renal impairment: In subjects with severe renal insufficiency (serum creatinine >6 mg/100 mL, i.e. >0.6 mmol/L) the half‑life of domperidone is increased from 7.4 to 20.8 hours, but plasma drug levels are lower than in subjects with normal renal function. Very little unchanged drug (approximately 1%) is excreted via the kidneys (see Dosage & Administration).
Toxicology: Non-Clinical Information: At a high, maternally toxic dose of 200 mg/kg/day, teratogenic effects (organ abnormalities such as anophthalmia, microphthalmia and displacement of the subclavian artery) were seen in the rat. The clinical significance of these findings is unknown. No teratogenicity was observed in mice and rabbits.
Electrophysiological in vitro and in vivo studies have shown that domperidone, at high concentrations, may prolong the QTc interval.
In juvenile rats, a no observed adverse effect level of 10 mg/kg was observed following 30 days of once daily repeat intraperitoneal dosing. Single intraperitoneal or intravenous doses showed similar LD₅₀ values (mean range 53‑76 mg/kg) in both juvenile and adult rats.

The dyspeptic symptom complex that is often associated with delayed gastric emptying, gastro‑esophageal reflux and esophagitis: epigastric sense of fullness, early satiety, feeling of abdominal distension, upper abdominal pain; bloating, eructation, flatulence; nausea and vomiting; heartburn with or without regurgitations of gastric contents in the mouth.
Nausea and vomiting of functional, organic, infectious or dietary origin.
Nausea and vomiting induced by: radiotherapy or drug therapy; dopamine agonists (such as L-dopa and bromocriptine) used in the treatment of Parkinson's disease.

It is recommended to take oral domperidone (Motilium) 15‑30 minutes before meals. If taken after meals, absorption of the drug is somewhat delayed.
When domperidone (Motilium) is used under medical supervision, the following dosing information applies: Adults and adolescents ≥12 years of age and weighing ≥35 kg, and children <12 years of age and weighing ≥35 kg: The dose of domperidone (Motilium) should be the lowest effective dose for the individual situation (typically 30 mg/day) and can be increased if necessary to a maximum daily oral dose of 40 mg.
Usually, the maximum treatment duration should not exceed one week for the treatment of acute nausea and vomiting. If nausea and vomiting persists for longer than one week, patients should consult their physician. For other indications, the initial duration of treatment is up to four weeks. If treatment exceeds four weeks, patients should be reevaluated and the need for continued treatment reassessed. (See Table 2.)

Click on icon to see table/diagram/image

Adults and adolescents (≥12 years of age) weighing <35 kg: The dose of domperidone (Motilium) should be the lowest effective dose. The total daily dose is dependent on body weight.
Usually, the maximum treatment duration should not exceed one week for the treatment of acute nausea and vomiting. For other indications, the initial duration of treatment is up to four weeks. If treatment exceeds four weeks, patients should be reevaluated and the need for continued treatment reassessed. Film‑coated tablets and orodispersible tablets are unsuitable for use in adults and adolescents weighing less than 35 kg.
Infants and children <12 years of age and weighing <35 kg: The efficacy of Motilium has not been established in infants and children <12 years of age and weighing <35 kg.
When Domperidone (Motilium) is used over‑the‑counter, the following dosing information applies: Adults and adolescents 12-60 years of age and weighing ≥35 kg: Domperidone (Motilium) can be taken as 10 mg administered up to 3 times a day to a maximum daily dose of 30 mg.
Continuous use of domperidone (Motilium) without medical consultation should not exceed 7 days for the treatment of acute nausea and vomiting and 14 days for dyspeptic symptom complex.
Adults >60 years of age: Patients older than 60 years of age should consult their physician before taking Domperidone (Motilium).
Infants and children <12 years old: Domperidone (Motilium) should not be administered to children <12 years old and weighing ≥35 kg unless prescribed for use.
The efficacy of Motilium has not been established in infants and children <12 years of age and weighing <35 kg.
Prescription and Non-prescription Use: Renal impairment: Since the elimination half‑life of domperidone is prolonged in severe renal impairment (serum creatinine >6 mg/100 mL, i.e. >0.6 mmol/L), the dosing frequency of domperidone (Motilium) should be reduced to once or twice daily, depending on the severity of the impairment, and the dose may need to be reduced. Patients with severe renal impairment should be reviewed regularly (see Pharmacology: Pharmacokinetics under Actions).
Hepatic impairment: Domperidone (Motilium) is contraindicated for patients with moderate (Child‑Pugh 7 to 9) or severe (Child‑Pugh >9) hepatic impairment (see Contraindications). Dose adjustment is not required for patients with mild (Child‑Pugh 5 to 6) hepatic impairment (see Pharmacology: Pharmacokinetics under Actions).

Symptoms and signs: Overdose has been reported primarily in infants and children. Symptoms of overdose may include agitation, altered consciousness, convulsion, disorientation, somnolence and extrapyramidal reactions.
Treatment: There is no specific antidote to domperidone. Close medical supervision and supportive therapy is recommended. Anticholinergic or anti‑Parkinson drugs may be helpful in controlling the extrapyramidal reactions.
It is advisable to contact a poison control center to obtain the latest recommendations for the management of an overdose.

Domperidone (Motilium) is contraindicated in the following situations: Known hypersensitivity to domperidone or any of the excipients.
Prolactin‑releasing pituitary tumour (prolactinoma).
Co-administration with potent CYP3A4 inhibitors (regardless of their QT prolonging effects) which have been shown to cause QT interval prolongation such as clarithromycin, erythromycin, itraconazole, oral ketoconazole, posaconazole, ritonavir, saquinavir, telithromycin, telaprevir, and voriconazole (see Precautions and Interactions).
Co-administration with QT-prolonging drugs, at the exception of apomorphine.
Whenever stimulation of gastric motility might be dangerous, e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction or perforation.
In patients with moderate or severe hepatic impairment (see Pharmacology: Pharmacokinetics under Actions).

Domperidone has been associated with prolongation of the QT interval on the electrocardiogram. During post-marketing surveillance, there have been very rare cases of QT prolongation and torsades de pointes in patients taking domperidone. These reports included patients with confounding risk factors, electrolyte abnormalities and concomitant treatment which may have been contributing factors.
Cardiac effects: Epidemiological studies have shown domperidone may be associated with an increased risk of serious ventricular arrhythmias or sudden cardiac death (see Adverse Reactions). Those studies suggest this increased risk may be higher in patients older than 60 years of age or in patients taking oral doses greater than 30 mg per day. Therefore, domperidone (Motilium) should be used with caution in older patients.
Patients older than 60 years of age should consult their physician before taking domperidone (Motilium).
Due to increased risk of ventricular arrhythmia, domperidone (Motilium) is not recommended in patients with known existing prolongation of cardiac conduction intervals, particularly QTc, in patients with significant electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia), or bradycardia, or in patients with underlying cardiac diseases such as congestive heart failure. Electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia) and bradycardia are known to be conditions increasing the proarrhythmic risk.
Treatment with domperidone (Motilium) should be stopped if signs or symptoms occur that may be associated with cardiac arrhythmia, and the patient should promptly consult their physician. Patients should be advised to promptly report any cardiac symptoms.
Drug interaction potential: The main metabolic pathway of domperidone is through CYP3A4. In vitro and human data show that the concomitant use of drugs that significantly inhibit this enzyme may result in increased plasma levels of domperidone. Co‑administration of domperidone with potent CYP3A4 inhibitors which have been shown to cause QT interval prolongation is contraindicated (see Contraindications).
Caution should be exercised when domperidone is co-administered with potent CYP3A4 inhibitors which have not been shown to cause QT interval prolongation such as indinavir and patients should be monitored closely for signs or symptoms of adverse reactions (see Adverse Reactions).
Caution should be exercised when domperidone is co‑administered with drugs which have been shown to cause QT interval prolongation and patients should be monitored closely for signs or symptoms of cardiovascular adverse reactions (see Adverse Reactions). Examples include: anti-arrhythmics class IA (e.g., disopyramide, quinidine); anti-arrhythmics class III (e.g., amiodarone, dofetilide, dronedarone, ibutilide, sotalol); certain antipsychotics (e.g., haloperidol, pimozide, sertindole); certain antidepressants (e.g., citalopram, escitalopram); certain antibiotics (e.g., levofloxacin, moxifloxacin); certain antifungal agents (e.g., pentamidine); certain antimalarial agents (e.g., halofantrine); certain gastro-intestinal drugs (e.g., dolasetron); certain drugs used in cancer (e.g., toremifene, vandetanib); certain other drugs (e.g., bepridil, methadone).
The previous list is representative and not exhaustive. Refer to relevant lists appropriate for the country.
Antacids or antisecretory agents should not be taken simultaneously with oral formulations of domperidone (Motilium) as they lower the oral bioavailability of domperidone. When used concomitantly, domperidone (Motilium) should be taken before meals and antacids or antisecretory agents after meals.
Excipients: The film‑coated tablet contains lactose and may be unsuitable for patients with lactose intolerance, galactosemia or glucose/galactose malabsorption.
Effects on Ability to Drive and Use Machines: Dizziness and somnolence have been observed following use of domperidone (see Adverse Reactions). Therefore, patients should be advised not to drive or use machinery or engage in other activities requiring mental alertness and coordination until they have established how domperidone (Motilium) affects them.

Pregnancy: There are limited post‑marketing data on the use of domperidone in pregnant women. A study in rats has shown reproductive toxicity at a high, maternally toxic dose. The potential risk for humans is unknown. Therefore, domperidone (Motilium) should only be used during pregnancy when justified by the anticipated therapeutic benefit.
Breast-feeding: The amount of domperidone that could be ingested by an infant through breast milk is low. The maximal relative infant dose (%) is estimated to be about 0.1% of the maternal weight‑adjusted dosage. It is not known whether this is harmful to the newborn. Therefore, breastfeeding is not recommended for women who are taking domperidone (Motilium).

Throughout this section, adverse reactions are presented. Adverse reactions are adverse events that were considered to be reasonably associated with the use of domperidone based on the comprehensive assessment of the available adverse event information. A causal relationship with domperidone cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Clinical Trial Data: The safety of domperidone (Motilium) was evaluated in 1,221 patients with gastroparesis, dyspepsia, gastro‑esophageal reflux disorder (GERD), or other related conditions in 45 clinical trials included in the safety database. All patients were ≥15 years old and received at least one dose of oral domperidone base. Slightly fewer than one‑half (553/1,221) of patients were diabetic. The median total daily dose was 80 mg (range 10 to 160 mg), with 230 patients receiving a dose greater than 80 mg. Median duration of exposure was 56 days (range 1 to 2,248 days).
ARs reported by ≥1% of patients treated with domperidone in these 45 clinical trials are shown in Table 3. (See Table 3.)

Click on icon to see table/diagram/image

ARs that occurred in <1% of domperidone-treated patients in the 45 clinical trials (n=1,221) are listed as follows in Table 4. (See Table 4.)

Click on icon to see table/diagram/image

The following adverse reaction has been reported with over-the-counter use: dry mouth.
Postmarketing: In addition to the ARs reported during clinical studies and listed previously, the following ADRs have been reported during postmarketing experience (Table 5). In the table, the frequencies are provided according to the following convention: Very common ≥1/10; Common ≥1/100 and <1/10; Uncommon ≥1/1,000 and <1/100; Rare ≥1/10,000 and <1/1,000; Very rare <1/10,000, including isolated reports.
In Table 5, ARs are presented by frequency category based on spontaneous reporting rates. (See Table 5.)

Click on icon to see table/diagram/image

Pediatric population: In postmarketing experience, there were no differences in the safety profile of adults and children.

The main metabolic pathway of domperidone is through CYP3A4. In vitro and human data show that the concomitant use of drugs that significantly inhibit this enzyme may result in increased plasma levels of domperidone.
When domperidone was co‑administered with potent CYP3A4 inhibitors which have been shown to cause QT interval prolongation, clinically relevant changes in QT intervals were observed. Therefore, co‑administration of domperidone with certain drugs is contraindicated (see Contraindications).
Caution should be exercised when domperidone is co‑administered with potent CYP3A4 inhibitors which have not been shown to cause QT interval prolongation or drugs which have been shown to cause QT interval prolongation (see Precautions).
Concomitant administration of anticholinergic drugs (e.g., dextromethorphan, diphenhydramine) may antagonize the anti‑dyspeptic effect of domperidone (Motilium). Theoretically, since domperidone (Motilium) has gastro-kinetic effects it could influence the absorption of concomitantly orally administered drugs, particularly those with sustained‑release or enteric‑coated formulations. However, in patients already stabilized on digoxin or paracetamol, concomitant administration of domperidone did not influence the blood levels of these drugs.
Domperidone (Motilium) may also be given with: neuroleptics, the action of which it does not potentiate; dopaminergic agonists (bromocriptine, L-dopa), whose unwanted peripheral effects such as digestive disorders, nausea and vomiting it suppresses without counteracting their central properties.

Incompatibilities: None known.

Store at temperatures not exceeding 30°C.

GIT Regulators, Antiflatulents & Anti-Inflammatories / Antiemetics

A03FA03 - domperidone ; Belongs to the class of propulsives. Used in the treatment of functional gastrointestinal disorders.

Rx